 Jeffrey Kaplan
Concepts (378)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biofilms | 39 | 2025 | 281 | 8.940 |
Why?
| | Aggregatibacter actinomycetemcomitans | 22 | 2024 | 27 | 3.910 |
Why?
| | Staphylococcus epidermidis | 15 | 2025 | 77 | 3.210 |
Why?
| | Glycoside Hydrolases | 14 | 2025 | 39 | 3.050 |
Why?
| | Bacterial Proteins | 24 | 2025 | 943 | 2.800 |
Why?
| | Anti-Bacterial Agents | 17 | 2025 | 1913 | 2.180 |
Why?
| | Polysaccharides, Bacterial | 13 | 2015 | 67 | 2.100 |
Why?
| | Bacterial Adhesion | 18 | 2018 | 109 | 2.000 |
Why?
| | Staphylococcus aureus | 9 | 2018 | 456 | 1.740 |
Why?
| | Actinobacillus pleuropneumoniae | 5 | 2013 | 5 | 1.400 |
Why?
| | DNA, Bacterial | 11 | 2024 | 341 | 1.390 |
Why?
| | Kingella kingae | 3 | 2016 | 12 | 1.210 |
Why?
| | Microbial Sensitivity Tests | 10 | 2025 | 373 | 0.990 |
Why?
| | Acetylglucosamine | 6 | 2008 | 13 | 0.930 |
Why?
| | Benzoyl Peroxide | 1 | 2025 | 2 | 0.910 |
Why?
| | Propionibacteriaceae | 1 | 2025 | 2 | 0.910 |
Why?
| | Propionibacterium acnes | 1 | 2025 | 10 | 0.900 |
Why?
| | Micrococcal Nuclease | 1 | 2024 | 26 | 0.840 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2024 | 249 | 0.840 |
Why?
| | Actinobacillus Infections | 7 | 2008 | 7 | 0.810 |
Why?
| | Prosthesis-Related Infections | 6 | 2011 | 99 | 0.810 |
Why?
| | Deoxyribonuclease I | 5 | 2018 | 38 | 0.770 |
Why?
| | Adhesins, Bacterial | 6 | 2010 | 46 | 0.740 |
Why?
| | Bacteria | 5 | 2014 | 894 | 0.700 |
Why?
| | Extracellular Space | 2 | 2012 | 132 | 0.680 |
Why?
| | Amoxicillin | 2 | 2024 | 35 | 0.670 |
Why?
| | Povidone-Iodine | 2 | 2018 | 11 | 0.650 |
Why?
| | Staphylococcal Skin Infections | 1 | 2018 | 41 | 0.550 |
Why?
| | Molecular Sequence Data | 17 | 2012 | 2914 | 0.530 |
Why?
| | Cetylpyridinium | 4 | 2009 | 7 | 0.500 |
Why?
| | Neisseriaceae Infections | 2 | 2016 | 6 | 0.500 |
Why?
| | beta-Lactams | 2 | 2016 | 32 | 0.480 |
Why?
| | Virulence Factors | 3 | 2024 | 172 | 0.450 |
Why?
| | Exotoxins | 4 | 2008 | 16 | 0.430 |
Why?
| | Pasteurellaceae | 3 | 2010 | 3 | 0.430 |
Why?
| | Genes, Bacterial | 5 | 2004 | 166 | 0.400 |
Why?
| | Genome, Bacterial | 2 | 2012 | 155 | 0.400 |
Why?
| | Bacterial Capsules | 1 | 2013 | 33 | 0.390 |
Why?
| | Arthritis, Infectious | 1 | 2012 | 72 | 0.340 |
Why?
| | Sodium Dodecyl Sulfate | 2 | 2009 | 26 | 0.340 |
Why?
| | Drug Resistance, Bacterial | 4 | 2018 | 198 | 0.330 |
Why?
| | Pasteurellaceae Infections | 2 | 2024 | 2 | 0.330 |
Why?
| | Recombination, Genetic | 1 | 2011 | 203 | 0.330 |
Why?
| | Fimbriae, Bacterial | 3 | 2016 | 35 | 0.320 |
Why?
| | Extracellular Matrix | 2 | 2014 | 564 | 0.320 |
Why?
| | Periodontitis | 5 | 2006 | 54 | 0.320 |
Why?
| | Staphylococcus | 2 | 2007 | 74 | 0.320 |
Why?
| | Pancreatic Neoplasms | 4 | 2024 | 943 | 0.310 |
Why?
| | Enzyme Therapy | 1 | 2009 | 3 | 0.310 |
Why?
| | beta-Glucans | 1 | 2008 | 16 | 0.290 |
Why?
| | Mouth | 2 | 2015 | 91 | 0.290 |
Why?
| | Down-Regulation | 1 | 2011 | 641 | 0.290 |
Why?
| | Aggressive Periodontitis | 3 | 2003 | 3 | 0.280 |
Why?
| | Polysaccharides | 2 | 2008 | 89 | 0.280 |
Why?
| | Haemophilus influenzae | 1 | 2009 | 67 | 0.280 |
Why?
| | Mouth Mucosa | 2 | 2007 | 89 | 0.280 |
Why?
| | Disinfectants | 1 | 2009 | 47 | 0.280 |
Why?
| | Fusobacterium nucleatum | 1 | 2008 | 4 | 0.280 |
Why?
| | Dental Plaque | 1 | 2008 | 19 | 0.280 |
Why?
| | Bacterial Infections | 1 | 2010 | 249 | 0.270 |
Why?
| | Cefamandole | 1 | 2007 | 1 | 0.260 |
Why?
| | Adenocarcinoma | 3 | 2024 | 936 | 0.260 |
Why?
| | Galactans | 1 | 2007 | 5 | 0.260 |
Why?
| | Polyurethanes | 1 | 2007 | 38 | 0.260 |
Why?
| | Bacterial Physiological Phenomena | 3 | 2014 | 60 | 0.260 |
Why?
| | Sequence Analysis, DNA | 6 | 2009 | 829 | 0.250 |
Why?
| | Surface-Active Agents | 1 | 2007 | 92 | 0.250 |
Why?
| | Humans | 45 | 2025 | 144848 | 0.250 |
Why?
| | Drug Resistance | 1 | 2007 | 154 | 0.240 |
Why?
| | Recombinant Proteins | 5 | 2018 | 1358 | 0.230 |
Why?
| | Swine Diseases | 1 | 2005 | 9 | 0.230 |
Why?
| | O Antigens | 2 | 2003 | 8 | 0.230 |
Why?
| | Acne Vulgaris | 1 | 2025 | 25 | 0.220 |
Why?
| | Fimbriae Proteins | 3 | 2016 | 23 | 0.210 |
Why?
| | Drug Synergism | 1 | 2025 | 364 | 0.210 |
Why?
| | Serotyping | 4 | 2008 | 32 | 0.210 |
Why?
| | Species Specificity | 4 | 2011 | 576 | 0.200 |
Why?
| | Acetylglucosaminidase | 1 | 2003 | 8 | 0.200 |
Why?
| | Animals | 17 | 2024 | 38331 | 0.200 |
Why?
| | Genetic Variation | 3 | 2002 | 991 | 0.190 |
Why?
| | Neisseria | 1 | 2002 | 2 | 0.190 |
Why?
| | Bacteria, Anaerobic | 1 | 2002 | 25 | 0.190 |
Why?
| | Base Sequence | 6 | 2012 | 2188 | 0.180 |
Why?
| | Gene Transfer, Horizontal | 2 | 2016 | 35 | 0.170 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2021 | 71 | 0.170 |
Why?
| | Gram-Negative Bacteria | 1 | 2001 | 79 | 0.160 |
Why?
| | Amino Acid Sequence | 7 | 2008 | 2149 | 0.160 |
Why?
| | Polymerase Chain Reaction | 5 | 2008 | 1058 | 0.160 |
Why?
| | Gastroesophageal Reflux | 1 | 2023 | 240 | 0.160 |
Why?
| | Osteopontin | 1 | 2020 | 34 | 0.160 |
Why?
| | Barrett Esophagus | 1 | 2023 | 165 | 0.160 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 40 | 0.160 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2021 | 196 | 0.160 |
Why?
| | Macrophages | 1 | 2008 | 1532 | 0.160 |
Why?
| | Microfluidics | 2 | 2010 | 62 | 0.150 |
Why?
| | Codon | 2 | 1998 | 96 | 0.150 |
Why?
| | DNA Transposable Elements | 4 | 2008 | 122 | 0.150 |
Why?
| | Polystyrenes | 3 | 2004 | 38 | 0.150 |
Why?
| | Esophageal Neoplasms | 1 | 2023 | 347 | 0.140 |
Why?
| | Microfluidic Analytical Techniques | 2 | 2010 | 81 | 0.140 |
Why?
| | Sus scrofa | 1 | 2018 | 64 | 0.140 |
Why?
| | Colony Count, Microbial | 2 | 2009 | 124 | 0.140 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.130 |
Why?
| | Escherichia coli | 5 | 2010 | 854 | 0.130 |
Why?
| | Weight Gain | 1 | 2021 | 560 | 0.130 |
Why?
| | Pancreatic Cyst | 1 | 2018 | 50 | 0.130 |
Why?
| | Liver | 2 | 2020 | 1853 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 265 | 0.130 |
Why?
| | Epithelial Cells | 3 | 2010 | 1133 | 0.130 |
Why?
| | Endopeptidase K | 1 | 2016 | 18 | 0.130 |
Why?
| | Biopsy | 2 | 2018 | 1071 | 0.130 |
Why?
| | Adipose Tissue | 1 | 2021 | 657 | 0.130 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 112 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 373 | 0.120 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2015 | 8 | 0.120 |
Why?
| | Mutagenesis, Insertional | 3 | 2008 | 67 | 0.110 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 390 | 0.110 |
Why?
| | Nausea | 1 | 2015 | 112 | 0.110 |
Why?
| | Myositis | 1 | 2015 | 57 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 151 | 0.110 |
Why?
| | Acinetobacter baumannii | 1 | 2014 | 24 | 0.110 |
Why?
| | Air | 1 | 2014 | 45 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2016 | 142 | 0.110 |
Why?
| | Bone Resorption | 1 | 2015 | 85 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 85 | 0.110 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2007 | 626 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2001 | 1184 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | Abdominal Pain | 1 | 2015 | 145 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2014 | 163 | 0.100 |
Why?
| | Anilides | 1 | 2014 | 83 | 0.100 |
Why?
| | Environmental Microbiology | 1 | 2014 | 57 | 0.100 |
Why?
| | Plankton | 1 | 2014 | 7 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 75 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2037 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 209 | 0.100 |
Why?
| | Surface Properties | 4 | 2012 | 412 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2019 | 782 | 0.100 |
Why?
| | Molecular Weight | 1 | 2013 | 325 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3633 | 0.090 |
Why?
| | Pancreas | 1 | 2014 | 342 | 0.090 |
Why?
| | Coated Materials, Biocompatible | 1 | 2012 | 65 | 0.090 |
Why?
| | Female | 15 | 2024 | 78213 | 0.090 |
Why?
| | Cell Survival | 3 | 2012 | 1113 | 0.090 |
Why?
| | Tobramycin | 1 | 2011 | 54 | 0.090 |
Why?
| | Microscopy, Electron | 2 | 2003 | 415 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4605 | 0.090 |
Why?
| | Cell Communication | 1 | 2013 | 326 | 0.080 |
Why?
| | Genetic Complementation Test | 2 | 2008 | 67 | 0.080 |
Why?
| | Culture Media | 3 | 2010 | 160 | 0.080 |
Why?
| | Orthopedic Equipment | 1 | 2010 | 5 | 0.080 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2014 | 308 | 0.080 |
Why?
| | Biomarkers, Tumor | 2 | 2014 | 1334 | 0.080 |
Why?
| | Treatment Failure | 1 | 2011 | 364 | 0.080 |
Why?
| | Focal Nodular Hyperplasia | 1 | 2010 | 7 | 0.080 |
Why?
| | Pyridines | 1 | 2014 | 616 | 0.080 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2002 | 564 | 0.080 |
Why?
| | Bacterial Toxins | 2 | 2002 | 108 | 0.080 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2007 | 62 | 0.080 |
Why?
| | Escherichia coli Proteins | 1 | 2011 | 207 | 0.080 |
Why?
| | Titanium | 1 | 2010 | 83 | 0.080 |
Why?
| | DNA Primers | 2 | 2007 | 517 | 0.080 |
Why?
| | Fungi | 1 | 2011 | 161 | 0.080 |
Why?
| | Disease Transmission, Infectious | 1 | 2010 | 68 | 0.080 |
Why?
| | Osteoblasts | 1 | 2010 | 145 | 0.070 |
Why?
| | Drug Interactions | 2 | 2008 | 399 | 0.070 |
Why?
| | Sodium Hypochlorite | 1 | 2009 | 5 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2010 | 141 | 0.070 |
Why?
| | Convection | 1 | 2008 | 7 | 0.070 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 321 | 0.070 |
Why?
| | Enzymes | 1 | 2009 | 64 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2008 | 392 | 0.070 |
Why?
| | Chlorhexidine | 1 | 2009 | 24 | 0.070 |
Why?
| | Mutation | 5 | 2009 | 4132 | 0.070 |
Why?
| | Flagella | 1 | 1989 | 27 | 0.070 |
Why?
| | Azo Compounds | 1 | 2008 | 30 | 0.070 |
Why?
| | Phosphoenolpyruvate Sugar Phosphotransferase System | 1 | 2008 | 4 | 0.070 |
Why?
| | Diffusion | 1 | 2008 | 123 | 0.070 |
Why?
| | Catalytic Domain | 2 | 2008 | 232 | 0.070 |
Why?
| | Caenorhabditis elegans | 1 | 2011 | 337 | 0.070 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2007 | 9 | 0.070 |
Why?
| | Obesity | 1 | 2021 | 3107 | 0.070 |
Why?
| | Congo Red | 1 | 2007 | 9 | 0.070 |
Why?
| | Phylogeny | 2 | 2002 | 1015 | 0.070 |
Why?
| | Gene Order | 1 | 2007 | 26 | 0.070 |
Why?
| | Male | 12 | 2024 | 72182 | 0.070 |
Why?
| | Tritium | 1 | 2007 | 68 | 0.070 |
Why?
| | Pancreatectomy | 2 | 2024 | 286 | 0.070 |
Why?
| | Detergents | 1 | 2007 | 44 | 0.070 |
Why?
| | Quorum Sensing | 1 | 2008 | 72 | 0.070 |
Why?
| | Micelles | 1 | 2007 | 40 | 0.070 |
Why?
| | Chromosomes, Bacterial | 1 | 2007 | 13 | 0.060 |
Why?
| | Ampicillin | 1 | 2007 | 15 | 0.060 |
Why?
| | Glycosyltransferases | 1 | 2007 | 15 | 0.060 |
Why?
| | Periodic Acid | 1 | 2007 | 2 | 0.060 |
Why?
| | Pancreatin | 1 | 2007 | 5 | 0.060 |
Why?
| | Ligands | 2 | 2008 | 674 | 0.060 |
Why?
| | Glycogen Storage Disease Type IV | 1 | 2006 | 3 | 0.060 |
Why?
| | 1,4-alpha-Glucan Branching Enzyme | 1 | 2006 | 3 | 0.060 |
Why?
| | Carbohydrate Sequence | 2 | 2008 | 29 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2014 | 851 | 0.060 |
Why?
| | Middle Aged | 8 | 2024 | 35939 | 0.060 |
Why?
| | Peptide Hydrolases | 1 | 2007 | 106 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2633 | 0.060 |
Why?
| | Cohort Studies | 3 | 2024 | 5898 | 0.060 |
Why?
| | Pleuropneumonia | 1 | 2005 | 1 | 0.060 |
Why?
| | Carbohydrate Conformation | 1 | 2005 | 15 | 0.060 |
Why?
| | Gene Deletion | 1 | 2007 | 388 | 0.060 |
Why?
| | Hydrogels | 2 | 2012 | 705 | 0.060 |
Why?
| | Static Electricity | 1 | 2005 | 111 | 0.060 |
Why?
| | Virulence | 2 | 2003 | 278 | 0.050 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 195 | 0.050 |
Why?
| | Mice | 5 | 2021 | 18549 | 0.050 |
Why?
| | Carbohydrate Metabolism | 1 | 2004 | 61 | 0.050 |
Why?
| | Primates | 1 | 2005 | 132 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 362 | 0.050 |
Why?
| | Aged | 6 | 2024 | 25822 | 0.050 |
Why?
| | Lactoferrin | 1 | 2003 | 36 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 182 | 0.050 |
Why?
| | Child, Preschool | 2 | 2016 | 11740 | 0.050 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 646 | 0.050 |
Why?
| | Metaplasia | 1 | 2023 | 58 | 0.050 |
Why?
| | Adult | 7 | 2020 | 40438 | 0.050 |
Why?
| | Transcription, Genetic | 3 | 2020 | 1506 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2224 | 0.050 |
Why?
| | Agar | 1 | 2002 | 11 | 0.050 |
Why?
| | Sequence Analysis, Protein | 1 | 2002 | 33 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 858 | 0.050 |
Why?
| | Bacteriological Techniques | 1 | 2003 | 68 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2010 | 792 | 0.050 |
Why?
| | Child | 3 | 2016 | 22620 | 0.050 |
Why?
| | Swine | 1 | 2005 | 843 | 0.050 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1257 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2002 | 243 | 0.050 |
Why?
| | DNA, Ribosomal | 1 | 2002 | 94 | 0.040 |
Why?
| | Mice, Obese | 1 | 2021 | 66 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2003 | 382 | 0.040 |
Why?
| | Esophagoscopy | 1 | 2023 | 218 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1471 | 0.040 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 76 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 99 | 0.040 |
Why?
| | Genotype | 2 | 2003 | 1841 | 0.040 |
Why?
| | Phenotype | 2 | 2010 | 3199 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 466 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2001 | 147 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1627 | 0.040 |
Why?
| | Tamoxifen | 1 | 2021 | 218 | 0.040 |
Why?
| | Protein Precursors | 1 | 2001 | 136 | 0.040 |
Why?
| | Mutagenesis | 1 | 2001 | 193 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1837 | 0.040 |
Why?
| | Coculture Techniques | 2 | 2010 | 251 | 0.040 |
Why?
| | Alleles | 1 | 2002 | 883 | 0.040 |
Why?
| | Temperature | 1 | 2002 | 684 | 0.040 |
Why?
| | Adolescent | 4 | 2010 | 22388 | 0.040 |
Why?
| | Protein Binding | 1 | 2005 | 2276 | 0.040 |
Why?
| | Genetic Code | 1 | 1998 | 25 | 0.030 |
Why?
| | Base Composition | 1 | 1998 | 79 | 0.030 |
Why?
| | ROC Curve | 1 | 2020 | 610 | 0.030 |
Why?
| | Cyst Fluid | 1 | 2018 | 20 | 0.030 |
Why?
| | Carcinoembryonic Antigen | 1 | 2018 | 38 | 0.030 |
Why?
| | Infant | 1 | 2012 | 9987 | 0.030 |
Why?
| | Cell Movement | 1 | 2002 | 977 | 0.030 |
Why?
| | Hydrolysis | 2 | 2008 | 201 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2018 | 51 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2018 | 59 | 0.030 |
Why?
| | Substrate Specificity | 2 | 2008 | 385 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2010 | 2934 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 992 | 0.030 |
Why?
| | Endosonography | 1 | 2018 | 157 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 37 | 0.030 |
Why?
| | Giant Cells | 1 | 2016 | 22 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1147 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8185 | 0.030 |
Why?
| | Binding Sites | 2 | 2010 | 1314 | 0.030 |
Why?
| | Cell Line | 2 | 2012 | 2911 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 11581 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 222 | 0.030 |
Why?
| | CD3 Complex | 1 | 2015 | 112 | 0.030 |
Why?
| | Monosaccharides | 1 | 2014 | 13 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1987 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 417 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2014 | 78 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 201 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2015 | 2538 | 0.030 |
Why?
| | Intestine, Small | 1 | 2015 | 167 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1967 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 108 | 0.030 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2014 | 192 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 7107 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 1060 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2018 | 1083 | 0.020 |
Why?
| | Lymphocytes | 1 | 2015 | 396 | 0.020 |
Why?
| | Microscopy | 1 | 2014 | 157 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 839 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 944 | 0.020 |
Why?
| | Colon | 1 | 2015 | 305 | 0.020 |
Why?
| | Models, Molecular | 2 | 2008 | 1603 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 290 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 692 | 0.020 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 236 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3628 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2881 | 0.020 |
Why?
| | Polymethacrylic Acids | 1 | 2012 | 61 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2014 | 384 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 442 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1531 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1829 | 0.020 |
Why?
| | Rats | 2 | 2015 | 5632 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 950 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1504 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 2051 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1193 | 0.020 |
Why?
| | Propidium | 1 | 2010 | 7 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2010 | 159 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 6067 | 0.020 |
Why?
| | Cell Shape | 1 | 2010 | 57 | 0.020 |
Why?
| | Alloys | 1 | 2010 | 38 | 0.020 |
Why?
| | Siphoviridae | 1 | 2009 | 2 | 0.020 |
Why?
| | Artificial Gene Fusion | 1 | 2009 | 3 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2009 | 5 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 379 | 0.020 |
Why?
| | Protein Hydrolysates | 1 | 2008 | 6 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2010 | 457 | 0.020 |
Why?
| | Nucleotides | 1 | 2009 | 126 | 0.020 |
Why?
| | Caseins | 1 | 2008 | 20 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 875 | 0.020 |
Why?
| | Buffers | 1 | 2008 | 56 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2009 | 276 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 423 | 0.020 |
Why?
| | Oligosaccharides | 1 | 2008 | 60 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1498 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2008 | 203 | 0.020 |
Why?
| | Multigene Family | 1 | 1989 | 204 | 0.020 |
Why?
| | Rifampin | 1 | 2008 | 81 | 0.020 |
Why?
| | Microscopy, Atomic Force | 1 | 2008 | 135 | 0.020 |
Why?
| | Orthopedics | 1 | 2010 | 160 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 406 | 0.020 |
Why?
| | Cercopithecidae | 1 | 2007 | 8 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2008 | 142 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2008 | 362 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2008 | 209 | 0.020 |
Why?
| | Phosphates | 1 | 2008 | 179 | 0.020 |
Why?
| | Teichoic Acids | 1 | 2007 | 18 | 0.020 |
Why?
| | Abortion, Eugenic | 1 | 2006 | 3 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 379 | 0.020 |
Why?
| | Thermodynamics | 1 | 2008 | 424 | 0.020 |
Why?
| | Equipment Design | 1 | 2008 | 534 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 2006 | 46 | 0.020 |
Why?
| | Knee Prosthesis | 1 | 2006 | 28 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 586 | 0.020 |
Why?
| | Hemolysis | 1 | 2008 | 244 | 0.020 |
Why?
| | Genome Components | 1 | 2006 | 2 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 564 | 0.010 |
Why?
| | Tissue Engineering | 1 | 2010 | 446 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4253 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 306 | 0.010 |
Why?
| | Protein Transport | 1 | 2007 | 445 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 154 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2012 | 2060 | 0.010 |
Why?
| | Calcium | 1 | 2010 | 1184 | 0.010 |
Why?
| | Spodoptera | 1 | 2003 | 40 | 0.010 |
Why?
| | Computer Simulation | 1 | 2008 | 1035 | 0.010 |
Why?
| | Alveolar Bone Loss | 1 | 2003 | 9 | 0.010 |
Why?
| | Genetic Testing | 1 | 2006 | 479 | 0.010 |
Why?
| | Maxilla | 1 | 2003 | 36 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2003 | 543 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2543 | 0.010 |
Why?
| | Adenosine Triphosphatases | 1 | 2003 | 162 | 0.010 |
Why?
| | Iron | 1 | 2003 | 357 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2003 | 620 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 5277 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1989 | 2860 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1430 | 0.010 |
Why?
| | United States | 1 | 2016 | 15720 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 16937 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6406 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2006 | 2108 | 0.010 |
Why?
| | Pregnancy | 1 | 2006 | 7197 | 0.010 |
Why?
|
|
Kaplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|